NEW CANAAN, CT—The Sabin Vaccine Institute presents its two highest non-science awards on May 30 to Jean-Pierre Garnier, PhD, Chairman and Chief Executive Officer of GlaxoSmithKline, and The Honorable Richard C. Holbrooke, Former U.S. Permanent Representative to the United Nations. Garnier will receive Sabin’s Humanitarian Award and Holbrooke will receive the Institute’s Lifetime Achievement Award at a benefit dinner at The Pierre Hotel in New York City.
“We are honoring two individuals this year both of whom are engaged strategically in the global effort to meet the health needs of populations whose vulnerability to disease is great, but whose resources are extremely limited,” said H.R. Shepherd, Chairman of the Sabin Vaccine Institute. “Richard Holbrooke has drawn upon his international profile to elevate disease prevention as an global priority and to redefine the great scourge of HIV/AIDS as a matter of global security.
Jean-Pierre Garnier’s corporate vision and leadership has been widely recognized and he has been an advocate for humanitarian efforts through which GlaxoSmithKline has engaged in international cooperation and independent disease prevention efforts to combat preventable childhood diseases, the great HIV/AIDS epidemic, and disfigurment of Lymphatic Filariasis.”
Heloisa Sabin, widow of the late Albert B. Sabin, will be on hand to introduce the Humanitarian Award recipient; William Haseltine, PhD, chairman of the board of Directors and CEO of Human Genome Sciences, Inc., will introduce announce the Lifetime Achievement winner. Colleagues of the honorees and corporate and individual supporters of the Sabin Vaccine Institute will be represented at the dinner in Garnier and Holbrooke’s honor. The awards dinner is a benefit for the Sabin Vaccine Institute. Co-chairs of the event are Jean Stéphenne, GlaxoSmithKline Biologicals, and Sanford I. Weill, Citigroup, Inc. The Honorable Hillary Rodham Clinton, United States Senate, served as Honorary Chair.
Previous recipients of the Sabin Humanitarian Award include Aventis Pasteur chairman and CEO Jean-Jacques Bertrand;Mary Flake de Flores, first lady of Honduras; Nicholas Zwick, founder of Dialogic Corporation (now part of Intel) and a philanthropist; and real estate developer and philanthropist Kathryn Thompson.
Previous Lifetime Achievement Award recipients include John W. Rowe, MD, chairman, president and chief executive officer of Aetna, Inc.; Merck & Co. CEO Raymond A. Gilmartin; and Vernon E. Loucks, Jr., former CEO of Baxter Healthcare Corporation.
The Albert B. Sabin Vaccine Institute’s mission is to prevent disease by stimulating development of new vaccines and increasing immunization rates. Founded in 1993, the Institute is headquartered in New Canaan, Connecticut. The Institute pursues Albert Sabin’s vision of a world protected from disease by vaccines. Sabin Institute colloquia bring together leaders of academia, industry, government and philanthropy in a shared quest to accelerate the development of vaccines to prevent infectious diseases and to prevent and treat cancer. As an immunization advocate, it helps policy makers shape sound public health policies and informs the public about the importance of vaccinations. The Sabin Institute’s Hookworm Vaccine Initiative is working to develop a vaccine to prevent an infection that afflicts more than twenty percent of the world’s population, a leading cause of malnutrition and stunted development.
About The Honorable Richard C. Holbrooke
Richard C. Holbrooke served as the U.S. Ambassador to the United Nations, where he was also a member of President Clinton's cabinet, from 1999 to 2001. In that capacity and others, he played a central role in the development of U.S. policy toward the United Nations, the Balkans, Africa, Asia, the Middle East and humanitarian crisis issues such as AIDS.
As Assistant Secretary of State for Europe from 1994 to 1996, Holbrooke was chief architect of the momentous 1995 Dayton peace agreement that ended the war in Bosnia. From 1993 to 1994 he was U.S. Ambassador to Germany. He later served as President Clinton's Special Envoy to Bosnia and Kosovo and as Special Envoy to Cyprus on a pro-bono basis while a private citizen.
From 1977 to 1981 he was Assistant Secretary of State for East Asian and Pacific Affairs and was in charge of U.S. relations with China when Sino-American relations were normalized in 1978. After joining the Foreign Service in 1962, he held assignments in Vietnam, the State Department and the White House. He was also Peace Corps Director in Morocco (1970-72), Managing Editor of Foreign Policy (1972-76), and held senior positions at two Wall Street firms.
In addition to his long career in diplomatic service, Holbrooke's experience includes posts as vice chairman of CS First Boston and as managing director of Lehman Brothers, where he utilized his leadership and strategic planning expertise to guide their growth nationally and globally.
Holbrooke has written numerous articles and two books: To End a War, a memoir of the Dayton negotiations, and, as co-author, Counsel to the President, Clark Clifford's memoir, as well as a volume of The Pentagon Papers. He holds 15 honorary degrees and numerous awards. A Board Member at the Council on Foreign Relations, he is working on a book on American diplomacy. He serves on the boards of AIG, the Asia Society, the American Museum of Natural History, The National Endowment for Democracy, Human Genome Sciences and Refugees International. He is Founding Chairman of The American Academy in Berlin, a center for U.S.-German cultural exchange, and President and CEO of the Global Business Council, the business alliance against HIV/AIDS. He is currently Vice Chairman of Perseus, a leading private equity firm.
About Jean-Pierre Garnier, PhD
Garnier is chief executive officer of GlaxoSmithKline. He assumed this role in December 2000 with the merger of SmithKline Beecham and Glaxo Wellcome. He joined SmithKline Beecham in 1990 as president of its pharmaceutical business in North America and served as chairman, Pharmaceuticals from 1994 until his appointment as chief operating officer in 1995. He was elected to the company’s Board of Directors in 1992. He became chief executive officer-elect in December 1999, and subsequently chief executive officer in April 2000.
Prior to SmithKline Beecham, Garnier served as president of Schering-Plough's U.S. business. During his 15 years at Schering, he held various management positions, including general manager of several overseas subsidiaries. In 1983, he joined the U.S. Pharmaceutical Products Division serving as vice president of marketing. He was then named senior vice president and general manager of the OTC business and assumed responsibility for sales and marketing for the U.S. prescription business prior to becoming president.
Garnier serves on the Boards of Directors of the United Technologies Corporation and the Eisenhower Exchange Fellowships, Inc. In January 1997, he was selected by President Jacques Chirac of France to receive the Chevalier de la Légion d'Honneur. Founded in 1802 by France's Emperor Napoleon I, the Légion honors individuals for their civilian or military accomplishments. In April 1997, he received from the Cancer Research Institute the Oliver R Grace Award for Distinguished Service in Advancing Cancer Research. In 2001, he was named one of 50 "Stars of Europe" by BusinessWeek magazine, presented with the Marco Polo Award for GlaxoSmithKline's commitment to China, and honored with the Corporate Citizenship Award from the Henry H. Kessler Foundation for the company's efforts to improve the lives of people with physical disabilities.
Dr Garnier holds a PhD in pharmacology and an MS in pharmaceutical science from the University of Louis Pasteur in France. As a Fulbright Scholar, he earned an MBA at Stanford University, California, in 1974.